Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Conditions
Acute Myeloid Leukemia
Conditions: official terms
Leukemia - Leukemia, Myeloid - Leukemia, Myeloid, Acute
Conditions: Keywords
AML, Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Study Type
Interventional
Study Phase
Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Ara-C Type: Drug
Name: BL-8040 Type: Drug
Overall Status
Recruiting
Summary
The goal of this clinical research study is to learn if BL-8040 in combination with cytarabine (Ara-C) can help to control the disease in patients with Acute Myeloid Leukemia (AML) that has relapsed or did not respond adequately to previous treatment. The safety of the study drug combination will also be studied.
Detailed Description
Open-label, multicenter, phase IIa, dose escalating study in subjects with relapsed/refractory AML, defined according to WHO criteria (1), including subjects who failed chemotherapy only and those who failed previous Autologous Stem Cell Transplantation (ASCT) / Allogeneic Stem Cell Transplantation (AlloSCT), provided at least 6 months have passed from transplant.

Eligible subjects will receive subcutaneous (SC) injections of BL-8040 ("monotherapy period") over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy ("combined period") over 5 days. During the "combined period," BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days and will not be escalated.

The first part of the study (Part 1) will include escalating dose groups and be considered the 'escalation phase'. Six potential dose levels (see Table 1) will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 and evaluated for dose escalation.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Adult men and women subjects aged 18 to 75, inclusive.

2. Confirmed diagnosis of relapsed/refractory AML (WHO criteria) Refractory subjects, up to second consecutive salvage . Relapsed subjects including first and second relapse.

3. AML relapse > 6 months since autologous or allogeneic stem cell transplantation, provided they are in first or second relapse and:

No active graft-versus-host disease (GVHD > grade 1). No treatment with high dose steroids for GVHD (up to 20 mg Prednisolone or equivalent, Appendix G). No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of 0.5-0.6 µg/mL).

4. Clinical laboratory values should be as follows:

WBC < 30,000/mL Blasts in PB ≤ 20,000. Treatment with Hydroxyurea is permitted up to 24 hrs prior to BL-8040 administration to achieve blast counts < 20,000 prior to enrollment. Creatinine < 1.3 mg/dL; if Creatinine is > 1 mg/dL the Creatinine clearance should be > 40 mL/min as calculated using the Cockcroft-Gault formula.

5. Women of childbearing potential and all men must agree to use an approved form of contraception (e.g. oral, transdermal patch, implanted contraceptives, intrauterine device, diaphragm, condom, abstinence or surgical sterility) prior to study entry and for the duration of study participation through 30 days after the last dose of BL-8040. Confirmation that female subjects are not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.

6. Subject is able and willing to comply with the requirements of the protocol.

7. Subject is able to voluntarily provide written informed consent.

Exclusion Criteria:

1. Administration of conventional chemotherapy within 2 weeks of enrollment date. In the event that subjects have received chemotherapy > 2 weeks from the date of enrollment, they may be included provided they have recovered from the associated non-hematological toxicities to ≤ grade 1.

2. Life expectancy of ≤ 2 months.

3. Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.

4. Use of investigational device or agents within 2 weeks of enrollment date.

5. Low Performance Status (ECOG > 2; Appendix E).

6. O2 saturation < 92% (on room air), evidence of TLS > grade 2 (according to the Cairo-Bishop criteria (3)) or leukostasis (2).

7. Abnormal liver function tests:

Serum aspartate transaminase (AST/SGOT) or alanine transaminase ( ALT/SGPT) 2 x upper limit of normal (ULN). Serum bilirubin. Total bilirubin > 2.0 mg/dL (34 µmol/L), conjugated bilirubin > 0.8 mg/dL.

8. Left ventricular ejection fraction < 40 %.

9. History of myocardial infarction or cerebrovascular accident within 6 months of enrollment date.

10. Presence of active, uncontrolled infection.

11. Known central nervous system disease (e.g., Alzheimer's disease).

12. Acute promyelocytic leukemia.

13. Exposure to high dose Ara-C within 6 months of enrollment.

14. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place him/her at unacceptable risk, including, but not limited to:

Subject has been diagnosed or treated for another malignancy within 3 years of enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer after curative therapy A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications.

15. Female subjects who are pregnant or breastfeeding.

16. Prior clinically significant grade 3-4 non-hematological toxicity to high dose Ara-C or grade ≥ 2 of neurological toxicity.

17. Seropositive for HIV antibodies (HIV1 and HIV2), Hepatitis C antibody (Hep C Ab) or a Hepatitis B carrier (positive for Hepatitis B surface antigen [HBsAg]).

18. Unable to comply with study requirements in the opinion of the Investigator.
Locations
Mayo Clinic
Jacksonville, Florida, United States
Status: Recruiting
Contact: Kathleen Burke, RN - 904-953-2955 - Burke.Kathleen@mayo.edu
Northwestern University-Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
Status: Recruiting
Contact: Jessica Altman, MD - 312-503-1817 - j-altman@northwestern.edu
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Martin Tallman, Prof - 212-639-3842 - TallmanM@mskcc.org
MD Anderson Cancer Center
Houston, Texas, United States
Status: Recruiting
Contact: Gautam Borthakur, MD - gborthak@mdanderson.org
Rambam Medical Center
Haifa, Israel
Status: Recruiting
Contact: Yishai Ofran, MD - y_ofran@rambam.health.gov.il
Hadassah University Hospital
Jerusalem, Israel
Status: Recruiting
Contact: Dina Ben-Yehuda, MD - dbyehuda@hadassah.org.il
Shaare Zedek Medical Center
Jerusalem, Israel
Status: Recruiting
Contact: Jacob M Rowe, MD - rowe@rambam.health.gov.il
Chaim Sheba Medical Center
Ramat Gan, Israel
Status: Recruiting
Contact: Amichai Shimoni, MD - Amichai.shimoni@sheba.health.gov.il
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Status: Recruiting
Contact: Nadav Sarid, MD - 972 3-697-3577 - nadavsarid@gmail.com
Start Date
April 2013
Completion Date
June 2015
Sponsors
BioLineRx, Ltd.
Source
BioLineRx, Ltd.
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page